



A service of the National Library of Medicine
and the National Institutes of Health

www.pubmed.gov

My NCBI
[Sign In] [Register]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search PubMed for prostate specific protein and NK-3

Preview

Go

Clear

☒ Limits

☐ Preview/Index

History

☐ Clipboard

☐ Details

Limits: **Publication Date to 1997/6/27**

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities

Search

Most Recent Queries

Time Result

**#1 Search prostate specific protein and NK-3 Limits:
Publication Date to 1997/6/27**

11:45:09

1

Clear History

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Sep 5 2006 08:10:00

WEST Search History

[Hide Items](#) | [Restore](#) | [Clear](#) | [Cancel](#)

DATE: Wednesday, September 13, 2006

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L10	prostate and NK-3	23
<input type="checkbox"/>	L9	prostate specific protein and Nk-3	0
<input type="checkbox"/>	L8	L7 and Nk-3	4
<input type="checkbox"/>	L7	L6 and prostate	51
<input type="checkbox"/>	L6	(carter kenneth)[IN]	142
<input type="checkbox"/>	L5	(carter kenneth)[IN] AND (prostate specific protein)	0
<input type="checkbox"/>	L4	(carter kenneth)[IN] AND (prostate protein)	0
<input type="checkbox"/>	L3	(carter kenneth c)[IN] AND (prostate protein)	0
<input type="checkbox"/>	L2	(he wei-wu)[IN] AND (prostate specific gene)	4
<input type="checkbox"/>	L1	(he wei-wu)[IN] AND (prostate specific protein)	0

END OF SEARCH HISTORY

Welcome to STN International! Enter x:x

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

```

NEWS      1      Web Page URLs for STN Seminar Schedule - N. America
NEWS      2      "Ask CAS" for self-help around the clock
NEWS      3      FEB 27  New STN AnaVist pricing effective March 1, 2006
NEWS      4      MAY 10  CA/CAPplus enhanced with 1900-1906 U.S. patent records
NEWS      5      MAY 11  KOREAPAT updates resume
NEWS      6      MAY 19  Derwent World Patents Index to be reloaded and enhanced
NEWS      7      MAY 30  IPC 8 Rolled-up Core codes added to CA/CAPplus and
                        USPATFULL/USPAT2
NEWS      8      MAY 30  The F-Term thesaurus is now available in CA/CAPplus
NEWS      9      JUN 02  The first reclassification of IPC codes now complete in
                        INPADOC
NEWS     10      JUN 26  TULSA/TULSA2 reloaded and enhanced with new search and
                        and display fields
NEWS     11      JUN 28  Price changes in full-text patent databases EPFULL and PCTFULL
NEWS     12      JUL 11  CHEMSAFE reloaded and enhanced
NEWS     13      JUL 14  FSTA enhanced with Japanese patents
NEWS     14      JUL 19  Coverage of Research Disclosure reinstated in DWPI
NEWS     15      AUG 09  INSPEC enhanced with 1898-1968 archive
NEWS     16      AUG 28  ADISCTI Reloaded and Enhanced
NEWS     17      AUG 30  CA(SM)/CAPplus(SM) Austrian patent law changes
NEWS     18      SEP 11  CA/CAPplus enhanced with more pre-1907 records

NEWS EXPRESS  JUNE 30  CURRENT WINDOWS VERSION IS V8.01b, CURRENT
                        MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
                        AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS LOGIN    Welcome Banner and News Items
NEWS IPC8      For general information regarding STN implementation of IPC 8
NEWS X25       X.25 communication option no longer available

```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:01:23 ON 13 SEP 2006

```
=> file caplus, bioeng, biotechno, biotechds, esbiobase
COST IN U.S. DOLLARS                               SINCE FILE          TOTAL
                                                    ENTRY          SESSION
FULL ESTIMATED COST                               0.21             0.21
```

FILE 'CAPLUS' ENTERED AT 12:01:53 ON 13 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOENG' ENTERED AT 12:01:53 ON 13 SEP 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHNO' ENTERED AT 12:01:53 ON 13 SEP 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHDS' ENTERED AT 12:01:53 ON 13 SEP 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'ESBIOBASE' ENTERED AT 12:01:53 ON 13 SEP 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s NK-3 and prostate and protein
L1 8 NK-3 AND PROSTATE AND PROTEIN

=> duplicate remove l1
DUPLICATE PREFERENCE IS 'CAPLUS, BIOTECHNO, BIOTECHDS, ESBIOBASE'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L1
L2 4 DUPLICATE REMOVE L1 (4 DUPLICATES REMOVED)

=> d l2 bib abs 1-4

L2 ANSWER 1 OF 4 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
AN 2004-08081 BIOTECHDS
TI Inhibiting neuronal cell death using neuronal marker genes and
proteins, useful for diagnosing, preventing and/or treating optic
nerve degeneration, Alzheimer's disease, diabetic retinopathy,
Parkinson's disease and glaucoma;
involving vector-mediated gene transfer and expression in host cell
for use in gene therapy
AU ZACK D J; QUIGLEY H A
PA UNIV JOHNS HOPKINS
PI WO 2004007675 22 Jan 2004
AI WO 2003-US21738 14 Jul 2003
PRAI US 2002-395821 15 Jul 2002; US 2002-395821 15 Jul 2002
DT Patent
LA English
OS WPI: 2004-122916 [12]
AN 2004-08081 BIOTECHDS
AB DERWENT ABSTRACT:
NOVELTY - Inhibiting neuronal cell death comprises administering to a
subject an isolated molecule comprising an antibody variable region which
specifically binds to a neuronal marker (NM1) protein, whereby
neuronal cell death is inhibited.
DETAILED DESCRIPTION - The neuronal marker (NM1) protein
in the method cited above is microglobulin, beta-2-microglobulin +
prostaglandin receptor F2a, glutathione S-transferase Yb subunit, GST
subunit 4 mu (GSTM2), vascular cell adhesion protein 1
precursor (V-CAM 1), gamma-aminobutyric acid (GABA) transporter 2, VGF8A
protein precursor, Transforming growth factor beta (TGF-beta)
masking protein large subunit, erythropoietin precursor (EPO),
protein arginine N-methyltransferase 1, signal transducer and
activator of transcription 3 (STATS), ceruloplasmin precursor (CP),
ferroxidase, clusterin (CLU), testosterone-repressed prostate
message 2 (TRPM2), apolipoprotein J, sulfated glycoprotein 2 (SGP2),
dimeric acid glycoprotein (DAG), heparin-binding growth factor 2
precursor (HBGF2), basic fibroblast growth factor (BFGF), fibroblast

growth factor 2 (FGF2), prostatropin, or plasminogen activator inhibitor 2A. INDEPENDENT CLAIMS are also included for the following: (1) a method of preventing neuronal cell death in a mammal, comprising administering to the mammal a nucleic acid molecule comprising a coding sequence for a neuronal marker (NM2) protein and/or the NM2 protein, whereby neuronal cell death in the mammal is inhibited or prevented; (2) method of identifying regions of neuronal cell death in a patient, comprising administering to a patient a molecule comprising an antibody variable region which specifically binds to NM1 protein, wherein the molecule is bound to a detectable moiety, and detecting the detectable moiety in the patient, thereby identifying regions of neuronal cell death; (3) a method of screening for neuronal cell death in a patient, comprising contacting a body fluid collected from the patient with a molecule comprising an antibody variable region which specifically binds to NM1 protein, or detecting an NM1 protein or a nucleic acid encoding the NM1 protein in a body fluid collected from the patient, wherein detection of cross-reactive material in the body fluid with the molecule indicates neuronal cell death in the patient; (4) a method of promoting neuronal cell death in a patient, comprising administering to a patient in need of neuronal cell death an NM1 protein or a nucleic acid molecule encoding the NM1 protein, whereby neuronal cell death in the patient is stimulated; and (5) a method to identify candidate drugs for treating neuronal cell death, comprising contacting cells which express one or more NM1 and/or NM2 genes and/or proteins with a test compound, determining expression or activity of the one or more NM1 genes and/or proteins by hybridization of mRNA of the cells to a nucleic acid probe which is complementary to the mRNA, and identifying a test compound as a candidate drug for treating neuronal cell death if it decreases expression or activity of the one and/or more NM1 and/or NM2 genes or proteins.

WIDER DISCLOSURE - Also disclosed are NM nucleic acids, polypeptides, host cells, vectors and antibodies used in the methods of the invention.

BIOTECHNOLOGY - Preferred Method: The NM2 protein is NM androgen binding protein, plasma kallikrein (rPK), Lim-2, embryonic motor neuron topographic organizer, HOMEODOMAIN PROTEIN LM-2 (LM/HOMEODOMAIN PROTEIN LHX5), DCC, netrin receptor, immunoglobulin gene superfamily member, former tumor suppressor protein candidate, N-myc proto-oncogene protein, M-phase inducer phosphatase 2 (MPI2), cell division control protein 25 B (CDC25B), von ebner's gland protein 2, VEG protein 2, VEGP2 + von ebner's gland protein 1, VEG protein 1, VEGP1, VEGP, synaptobrevin 1 (SYB1), vesicle-associated membrane protein 1 (VAMP1), 3-methylcholanthrene-inducible cytochrome P450 (P450MC), cytochrome P450 IAL (CYP1A1), cytochrome P450 VU (CYP7), cholesterol 7-alpha-monooxygenase, cholesterol 7-alpha-hydroxylase, cyclic nucleotide-activated channel, olfactory, cytochrome P450 2E1 (CYP2E1), P450-J, P450RLM6, high affinity L-proline transporter, neuronal acetylcholine receptor protein alpha-3 chain precursor, sodium channel I, voltage-dependent L-type calcium channel alpha 1C subunit (CACNA1), cardiac muscle L-type calcium channel alpha 1 polypeptide isoform 1 (CCHL1A1), rat brain class C (RBC), CACH2, CACN2, ATPase, hydrogen-potassium, alpha 2a subunit, sodium channel, amiloride sensitive, alpha subunit, SCNEA, alpha NACH, SCNN1A, RENAC, cardiac specific sodium channel alpha subunit, potassium channel protein CDRK, neuronal acetylcholine receptor protein alpha 5 subunit precursor (CHRNA5, ACRA5), sodium channel SHRSPhD, gamma subunit, epithelial, sodium channel protein 6 (SCP6), renal organic anion transporter (ROAT1) + multispecific organic anion transporter (OAT1), neuronal acetylcholine receptor protein alpha 6 subunit precursor (CHRNA6, ACRA6), purinergic receptor P2X3, ligand-gated ion channel, calcium channel, alpha 1 beta, sodium channel, beta 1 subunit,

neuronal acetylcholine receptor protein alpha 7 subunit precursor (CHRNA7, ACRA7), neuronal nicotinic acetylcholine receptor alpha 2 subunit, proton gated cation channel drasic, sensory neuron specific, channel-inducing factor precursor (CHIP), corticosteroid-induced protein, MYELM BASIC PROTEIN S (MBPS), organic cation transporter 2 (OCT2), ASIC1 proton gated cation channel, glycine receptor alpha 3 subunit precursor (GLRA3), voltage-gated K+ channel protein, RK5, potassium channel protein, voltage-activated calcium channel alpha-1 subunit (RBE-II), nickel-sensitive T-type calcium channel alpha-1 subunit, inward rectifier potassium channel subfamily J member 2 (KCNJ2), RBL-IRK1, eek proto-oncogene, protein tyrosine kinase, eph/elk-related, prostaglandin D2 receptor, activin receptor type I precursor (ACVR1, ACTR1), serine/threonine-protein kinase receptor R1 (SKR1), TGF-B superfamily receptor type I (TSR-I), ACVRLK2, calcitonin receptor precursor (CT-R), ClAJC1E, prostaglandin E2 receptor EP2 subtype (PGE receptor EP2 subtype, PTGER2), prostanoid EP2 receptor, NEUREXINI-BETA PRECURSOR, Non-processed neurexin I-beta Synaptic cell surface proteins + NEUREXIN I-ALPHA PRECURSOR, Non-processed neurexin I-alpha Synaptic cell surface proteins, gastrin-releasing peptide precursor (GRP), neuromedin C, serotonin receptor, 5-hydroxytryptamine 6 receptor (5-HT-6), ST-B17, possesses high affinity for tricyclic psychotropic drugs, platelet activating factor receptor, alpha 2B adrenergic receptor (ADRA2B), alpha 2B adrenoceptor, VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2 PRECURSOR (VIP-R-2) (PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE TYPE M RECEPTOR) (PACAP TYPE M RECEPTOR) PACAP-R-3), transforming growth factor beta 3 (TGF-beta3), antiproliferative growth factor, vasopressin V1b receptor, prostaglandin E2 receptor EP4 subtype, alpha 2C adrenergic receptor (ADRA2C), alpha 2C adrenoceptor, vasopressin/arginine receptor, Via, prostaglandin F2 alpha receptor, growth hormone secretagogue receptor 1 (GHSR), cholecystokinin receptor, NMDAR2A N-METHYL-D-ASPARTATE RECEPTOR SUBUNIT, P2U PURINOCEPTOR 1 (ATP RECEPTOR) (P2U1) PURINERGIC RECEPTOR), estrogen receptor beta (ER-beta), ESR2, NR3A2, kappa-type opioid receptor (KOR-I), lutropin-choriogonadotropic hormone receptor, beta 1 adrenergic receptor (ADRB1R), 5-hydroxytryptamine (serotonin) receptor 1B, 5-HT1B, adrenergic receptor, beta 2, muscarinic acetylcholine receptor M3 (MACHR), B1 bradykinin receptor, mu opioid receptor (MUOR1), mu-type opioid receptor (MOR-I), opioid receptor B, serotonin 5HT2 receptor, somatostatin receptor 2, melatonin receptor, somatostatin receptor, galanin receptor 1, neuromedin B receptor, transmembrane receptor UNC5H1, pancreatic polypeptide receptor PPl, interleukin-2 QL-2), somatostatin, luteinizing hormone, alpha, mast cell protease 1 precursor (RMCP-I), secretory protein probasin (M-40), E-selectin precursor, endothelial leukocyte adhesion molecule 1 (ELAM-I), leukocyte-endothelial cell adhesion molecule 2 (LECAM2), CD62E, Protein kinase C-binding protein betals, RING-domain containing, kidney band 3 anion exchange protein, SLC4A1, AE1, L-selectin precursor, lymph node homing receptor, leukocyte adhesion molecule-1 (LAM-1), LY-22, lymphocyte surface MEL-14 antigen, leukocyte-endothelial cell adhesion molecule 1 (LECAM1), CD62L, Wilms1 tumor protein (WT1), tumor suppressor, CD28, T-cell surface antigen, c-fgr proto-oncogene, CD3, gamma chain, cathepsin E, S-myc proto-oncogene protein, myc-related, G protein-activated inward rectifier potassium channel 4 (GIRK4), inward rectifier potassium channel subfamily J member 5 (KCNJ5), heart KATP channel, KATP-I, cardiac inward rectifier (CIR), KIR3.4, fructose (glucose) transporter, sodium channel protein 6 (SCP6), sodium channel, beta 1 subunit, sodium-hydrogen exchange protein -isoform 2 (NHE-2), PMCA, ATP2B2, calcium-transporting ATPase plasma membrane (brain isoform 2, EC 3.6.1.38), calcium pump, ATPase, sodium/potassium, gamma subunit, G protein-activated inward rectifier potassium channel 1 (GIRK1), inward rectifier potassium channel subfamily J member 3 (KCNJ3), KGA, KGB1, KIR3.1, proton gated cation channel drasic, sensory neuron specific, sodium channel 2, brain ATPase,

copper-transporting, Menkes protein, channel-inducing factor precursor (CHIF), corticosteroid-induced protein, synaptotagmin II, carbonic anhydrase 4, calcitonin receptor precursor (CT-R), C1A/C1B, vasopressin V2 receptor, 5-hydroxytryptamine (serotonin) receptor IB, 5-HT1B, gamma-aminobutyric acid receptor alpha 4 subunit precursor (GABA(A) receptor, GABRA4), vitamin D3 receptor (VDR), 1,25-dihydroxyvitamin D-3 receptor, NR1I1, muscarinic acetylcholine receptor M5 (CHRM5), somatostatin receptor, galanin receptor 1, granulocyte-macrophage colony-stimulating factor (GM-CSF), colony-stimulating factor (CSF), guanylyl cyclase (membrane form), parathyroid hormone receptor PTH2, galanin receptor 2, 5-hydroxytryptamine (serotonin) receptor 2B, guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-7 subunit (GNG7, GNGT7), adenylyl cyclase 4, protein kinase C-binding protein nel homolog 1, phospholipase C beta 3 (PLC-beta 3), tissue-type plasminogen activator (t-PA), NW, neural visinin-like Ca2+-binding protein, VISININ-LIKE PROTEIN 1 (VOM) (NEURAL VISMM-LIKE PROTEIN 1) (NVL-I) (NVP-I) (21KD CABP), T-cell receptor CD3 zeta subunit, P-selectin precursor, granule membrane protein 140 (GMP-140), PADGEM, CD62P, leukocyte-endothelial cell adhesion molecule 3 (LECAM3), T-cell receptor gamma subunit, kidney band 3 anion exchange protein, SLC4A1, AEL, L-selectin precursor, lymph node homing receptor, leukocyte adhesion molecule-1 (LAM-1), LY-22, lymphocyte surface MEL-14 antigen, leukocyte-endothelial cell adhesion molecule 1 (LECAM1), CD62L, myelin PO protein precursor, MPZ, MAL, T-lymphocyte maturation-associated protein, myelin protein MVP17, ErbB3 EGF receptor-related proto-oncogene, HER3, CD 30L receptor, lymphocyte activation antigen CD30, Ki-I antigen, CD30 precursor, zinc transporter (ZnT-I), CCHB3, calcium channel (voltage-gated), DIHYDROPYRIDINEB-SENSITIVE L-TYPE, CALCIUM CHANNEL BETA-3 SUBUNIT, water channel aquaporin 3 (AQP3), 3-methylcholanthrene-inducible cytochrome P450 (P450MC), cytochrome P450 IAL (CYP1A1), sodium/potassium-transporting ATPase beta 1 subunit (ATP1B1), glucose transporter 3, ATP-sensitive inward rectifier potassium subfamily J member 8 (KCNJ8), UKATP-I, ATP-sensitive inwardly rectifying K+ channel KIR6.1, RJM, Rab3 effector in synaptic-vesicle fusion, neuronal acetylcholine receptor protein alpha-3 chain precursor, purmergic receptor P2X5, ligand-gated ion channel, sodium channel I, renal organic anion transporter (ROAT1) H- multispecific organic anion transporter (OAT1), neuronal acetylcholine receptor protein alpha 6 subunit precursor (CHRNA6, ACRA6), sodium channel, beta 1 subunit, sodium-hydrogen exchange protein-isoform 2 (NHE-2), PMCA, ATP2B2, calcium-transporting ATPase plasma membrane (brain isoform 2, EC 3.6.1.38), calcium pump, fibrinogen beta subunit (FGB), sulfonylurea receptor (SUR), glycine receptor alpha 3 subunit precursor (GLRA3), multidrug resistance protein 2 (MDR2), P-glycoprotein (PGY2), potassium channel, voltage gated, KV3.4, RAW3, KCNC4, sodium/chloride co-transporter, thiazide sensitive, synaptosomal associated protein 25, SNAP-25, SNAP, SNAP25, SUP, calcitonin receptor precursor (CT-R), C1A/C1B, gamma-aminobutyric acid (GABA-A) receptor, beta 1 subunit, NEUREXIN1-BETA PRECURSOR, Non-processed neurexin I-beta Synaptic cell surface proteins + NEUREXIN I-ALPHA PRECURSOR, Non-processed neurexin I-alpha Synaptic cell surface proteins, alpha 2B adrenergic receptor (ADRA2B), alpha 2B adrenoceptor, neuropeptide Y receptor type 1, prostaglandin E2 receptor EP4 subtype, alpha 2C adrenergic receptor (ADRA2C), alpha 2C adrenoceptor, c-ErbA oncogene, thyroid hormone receptor alpha-1 (THRA1), gamma-aminobutyric acid receptor alpha 1 subunit precursor (GABA(A) receptor, (GABRA2), P2Y PURINOCEPTOR 6 (P2Y6), glutamate receptor 1 precursor (GluR-I), GluR-A, GluR-K1, gamma-aminobutyric acid receptor alpha 3 subunit precursor (GABA(A) receptor, GABRA3), NMDAR2A N-METHYL-D-ASPARTATE RECEPTOR SUBUNIT, P2U PURMOCEPTOR 1 (ATP RECEPTOR) (P2U1) (PURMBRGIC RECEPTOR), 5-hydroxytryptamine (serotonin) receptor IB, 5-HTIB, glycine receptor, alpha 2A subunit, inhibitory, parathyroid

hormone receptor PTH2, 5-hydroxytryptamine 5A receptor (5HT5A, HTR5A), serotonin receptor, REC17, acetylcholine receptor alpha, brain natriuretic peptide (BNP), 5-kDa cardiac natriuretic peptide, ISO-ANP, luteinizing hormone, alpha, cocaine/amphetamine-induced rat transcript, CART, protein kinase C-binding protein nel homolog 1, 14-3-3 protein eta, PKC inhibitor protein-1, KCIP-I, plectin, NVP, neural visinin-like Ca²⁺-binding protein, VISININ-LIKE PROTEIN 1 (VILIP-I) (NEURAL VISININ-LIKE PROTEIN 1) (NVL-I) (NVP-I) (21 KD CABP), syndecan 3, ras-GTPase-activating protein (GAP), ras p21 protein activator, p20GAP, interleukin-6 receptor beta chain, membrane glycoprotein gp150, prostatic secretory protein probasin (M-40), A-raf proto-oncogene, prothymosin-alpha (PTMA), cadherin 6 precursor, kidney-cadherin (K-cadherin), neurofibromin, neurofibromatosis protein type I (NF1), GTPase stimulatory protein, c-H-ras proto-oncogene, transforming G-protein p21, HSP84, HSP90-beta, heat shock 90kD protein, Neural adhesion molecule F3, RAT NEURAL ADHESION MOLECULE F3, COMPLETE CDS, BIG-1 PROTEIN PRECURSOR, neural cell adhesion protein, neurite outgrowth-promotor, potassium channel protein, KSH1HA3, ATP-sensitive inward rectifier potassium channel subfamily J member 1 (KCNJ1), KAB-I, KIR1. 1, ROMK1, Band 3 (B3RP3), 3 Cl-HCO₃-anion exchanger, voltage-gated potassium channel protein KV1. 1, RBK1, RCK1, KCNA1, potassium channel, inward rectifier 9, taurine transporter, neuronal acetylcholine receptor protein alpha-3 chain precursor, sodium channel I, potassium channel protein CDRK, neuronal acetylcholine receptor protein alpha 6 subunit precursor (CHRNA6, ACRA6), calcium channel, alpha 1 beta, sodium channel, beta 1 subunit, PMCA, ATP2B2, calcium-transporting ATPase plasma membrane (brain isoform 2, EC 3.6.1.38), calcium pump, 17-kDa ubiquitin-conjugating enzyme E2 (UBE2B), ubiquitin-protein ligase, ubiquitin carrier protein, HR6B, synaptosomal associated protein 25, SNAP-25, SNAP, SNAP25, SUP, 67-kDa glutamic acid decarboxylase (GAD67), GAD1, eek proto-oncogene, protein tyrosine kinase, eph/elk-related, D(IA) DOPAMINE RECEPTOR, growth hormone receptor precursor (GH receptor, GHR), serum-binding protein, NMDAR2A N-METHYL-D-ASPARTATE RECEPTOR SUBUNIT, 5-hydroxytryptamine (serotonin) receptor 1B, 5-HT1B, thyroid hormone beta receptor, c-erbA-beta, gamma-aminobutyric acid (GABA-A) receptor, beta 3 subunit, glutamate receptor 2 precursor (GLUR-2, GLUR-B, GLUR-K2), glutamate receptor 4 precursor (GLUR-4, GLUR-D), cannabinoid receptor 1, neuronal, neuromedin K receptor (NKR), neurokinin B receptor, NK-3 receptor (NK-3R), GABA-A receptor gamma-2 subunit precursor, galanin receptor 2, insulin-like growth factor binding protein 1 precursor (IGFBP-I, IBP-I), pre-somatotropin, protein kinase C beta-I type (PKC-beta I) + protein kinase C beta-II type (PKC-beta D), guanine nucleotide-binding protein G(O) alpha subunit (GNAO, GNAO), guanine nucleotide-binding protein G(I) alpha 1 subunit (GNAI1), adenylate cyclase-inhibiting G alpha protein, serine/threonine kinase PCTAIRE2 (PCTK2), protein kinase C-binding protein nel homolog 1, PKI-alpha, CAMP-dependent protein kinase inhibitor (muscle/brain form), 14-3-3 protein eta, PKC inhibitor protein-1, KCIP-I, and NW, or neural visinin-like Ca²⁺-binding protein, VISININ-LIKE PROTEIN 1 (VILIP-I) (NEURALVISININ-LIKE PROTEIN 1) (NVL-I) (NVP-I) (21 KD CABP).

ACTIVITY - Ophthalmologic; Nootropic; Neuroprotective; Antidiabetic; Anticonvulsant; Vulnerary; Antiparkinsonian; Cytostatic. No biological data given.

MECHANISM OF ACTION - Gene-Therapy.

USE - The methods and compositions are useful for the diagnosis, prevention and/or treatment of diseases or conditions associated with neuronal cell death, such as optic nerve degeneration, Alzheimer's disease, diabetic retinopathy, Huntington's disease, spinal cord injury,

Parkinson's disease, glaucoma, neuronal tumor and age-related macular degeneration (claimed).

ADMINISTRATION - Routes of administration of the pharmaceutical compositions include intramuscular, intraperitoneal, intravenous, subcutaneous, intrarectal, transdermal and intranasal. No dosages given.

EXAMPLE - No relevant example given.(122 pages)

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
AN 2000:472152 CAPLUS
DN 133:204315
TI DNA-binding sequence of the human prostate-specific homeodomain protein NKX3.1
AU Steadman, David J.; Giuffrida, Domenica; Gelmann, Edward P.
CS Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, DC, 20007-2197, USA
SO Nucleic Acids Research (2000), 28(12), 2389-2395
CODEN: NARHAD; ISSN: 0305-1048
PB Oxford University Press
DT Journal
LA English
AB NKX3.1 is a member of the NK class of homeodomain proteins and is most closely related to Drosophila NK-3. NKX3.1 has predominantly prostate-specific expression in the adult human. Previous studies suggested that NKX3.1 exerts a growth-suppressive effect on prostatic epithelial cells and controls differentiated glandular functions. Using a binding site selection assay with recombinant NKX3.1 protein we identified a TAAGTA consensus binding sequence that has not been reported for any other NK class homeoprotein. By electromobility shift assay we demonstrated that NKX3.1 preferentially binds the TAAGTA sequence rather than the binding site for Nkx2.1 (CAAGTG) or Msx1 (TAATTG). Using mutated binding sites in competitive gel shift assays, we analyzed the nucleotides in the TAAGTA consensus sequence that are important for NKX3.1 binding. The consensus binding site of a naturally occurring polymorphic NKX3.1 protein with arginine replaced by cysteine at position 52 was identical to the wild-type binding sequence. The binding affinities of wild-type and polymorphic NKX3.1 for the TAAGTA consensus site were very similar, with values of 20 and 22 nM, resp. Wild-type and polymorphic NKX3.1 specifically repressed transcription of luciferase from a reporter vector with three copies of the NKX3.1-binding site upstream from a thymidine kinase promoter. The data show that among NK family proteins NKX3.1 binds a novel DNA sequence and can behave as an in vitro transcriptional repressor.

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:35000 CAPLUS
DN 130:106044
TI Human prostate specific gene NKX3.1 and protein and diagnosis and treatment of cancer
IN Carter, Kenneth C.; He, Wei-wu
PA Human Genome Sciences, Inc., USA
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9900498	A1	19990107	WO 1998-US13252	19980626
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2295303	AA	19990107	CA 1998-2295303	19980626

EP 996725 A1 20000503 EP 1998-931606 19980626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

JP 2002510974 T2 20020409 JP 1999-505740 19980626
US 2003022275 A1 20030130 US 1998-105470 19980626
US 6617129 B2 20030909

PRAI US 1997-51080P P 19970627
WO 1998-US13252 W 19980626

AB The present invention relates to a novel member of the NK family of homeobox genes. In particular, isolated nucleic acid mols. are provided encoding the human NK-3 prostate specific gene 1 (NKX3.1) protein. NKX3.1 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of NKX3.1 activity. Also provided are diagnostic methods for detecting prostate cancer and other cancers and therapeutic methods for prostate cancer and other cancers. Thus, cDNA for the prostate-specific human gene NKX3.1, which maps to 8p21 and encodes a homeodomain-containing protein related to the Drosophila NK gene family, was cloned. The gene may play a role in both prostate development and the androgen-driven maintenance of prostatic differentiation in adults. The expression of NKX3.1 in adult humans was found to be restricted to prostate and testes. When assayed in several cell lines, including 3 lines derived from prostate carcinoma tissue, the gene was expressed solely in the androgen-dependent prostate carcinoma cell line LNCaP. In these cells, NKX3.1 gene expression is regulated by androgens. The new gene NKX3.1 is a candidate for playing a central role in the opposing processes of androgen-driven differentiation of prostatic tissue and loss of that differentiation during the progression of prostate cancer.

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

AN 1997:21335 CAPLUS

DN 126:184178

TI Prostate-specific and androgen-dependent expression of a novel homeobox gene

AU Bieberich, Charles J.; Fujita, Kazuyuki; He, Wei-Wu; Jay, Gilbert

CS Dep. Virol., Jerome H. Holland Lab., Rockville, MD, 20855, USA

SO Journal of Biological Chemistry (1996), 271(50), 31779-31782

CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB A new member of the mouse NK family of homeobox genes that is related to Drosophila NK-3 has been identified. Expression of this gene, termed Nkx-3.1, is largely restricted to the prostate gland in adult animals. The level of Nkx-3.1 mRNA decreases markedly in response to castration, suggesting that its expression is androgen-dependent. In situ hybridization analyses demonstrated that expression of Nkx-3.1 in the prostate is confined to epithelial cells. In newborns, Nkx-3.1 mRNA is detected in the urethral epithelium that is being induced by the surrounding mesenchyme to invaginate to form prostatic buds. Together, these observations suggest that the Nkx-3.1 protein, which likely functions as a transcription factor, plays a prominent role both in the initiation of prostate development and in the maintenance of the differentiated state of prostatic epithelial cells.

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

Welcome to DialogClassic Web(tm)

Dialog level 05.12.03D

Last logoff: 06sep06 14:59:16

Logon file001 13sep06 11:11:35

*** ANNOUNCEMENTS ***

NEW FILES RELEASED

***Verdict Market Research (File 769)

***EMCare (File 45)

***Trademarkscan - South Korea (File 655)

***Regulatory Affairs Journals (File 183)

***Index Chemicus (File 302)

***Inspec (File 202)

RESUMED UPDATING

***File 141, Reader's Guide Abstracts

RELOADS COMPLETED

***File 11, PsycInfo

***File 531, American Business Directory

*** The 2005 reload of the CLAIMS files (Files 340, 341, 942)
is now available online.

DATABASES REMOVED

***File 196, FINDEX

***File 468, Public Opinion Online (POLL)

Chemical Structure Searching now available in Prous Science Drug
Data Report (F452), Prous Science Drugs of the Future (F453),
IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein
Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus
(File 302).

>>>For the latest news about Dialog products, services, content<<<
>>>and events, please visit What's New from Dialog at <<<
>>><http://www.dialog.com/whatsnew/>. You can find news about<<<
>>>a specific database by entering HELP NEWS <file number>.<<<

* * *

File 1:ERIC 1966-2006/Aug

(c) format only 2006 Dialog

Set Items Description

--- -----

Cost is in DialUnits

?

B 155, 159, 10, 203, 35, 5, 467, 73, 434, 34

13sep06 11:12:02 User290558 Session D74.1

\$1.03 0.294 DialUnits File1

\$1.03 Estimated cost File1

\$0.13 INTERNET

\$1.16 Estimated cost this search

\$1.16 Estimated total session cost 0.294 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1950-2006/Sep 12

(c) format only 2006 Dialog

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog

*File 159: Cancerlit is no longer updating.

Please see HELP NEWS159.

File 10:AGRICOLA 70-2006/Aug
 (c) format only 2006 Dialog
 File 203:AGRIS 1974-2006/Jun
 Dist by NAL, Intl Copr. All rights reserved
 File 35:Dissertation Abs Online 1861-2006/Aug
 (c) 2006 ProQuest Info&Learning
 File 5:Biosis Previews(R) 1969-2006/Sep W1
 (c) 2006 The Thomson Corporation
 File 467:ExtraMED(tm) 2000/Dec
 (c) 2001 Informania Ltd.
 File 73:EMBASE 1974-2006/Sep 12
 (c) 2006 Elsevier B.V.
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
 (c) 2006 The Thomson Corp
 File 34:SciSearch(R) Cited Ref Sci 1990-2006/Sep W1
 (c) 2006 The Thomson Corp

Set	Items	Description
---	-----	-----

?

S NK-3 AND PROSTATE AND PROTEIN

	74	NK-3
	352181	PROSTATE
	6879478	PROTEIN
S1	0	NK-3 AND PROSTATE AND PROTEIN

?

S NK (N) 3 AND PROSTATE

Processing

Processed 10 of 10 files ...

Completed processing all files

	115237	NK
	12311711	3
	1926	NK(N)3
	352181	PROSTATE
S2	15	NK (N) 3 AND PROSTATE

?

RD S2

S3	5	RD S2 (unique items)
----	---	----------------------

?

TYPE S3/FULL/1-5

3/9/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

14025484 PMID: 12450213

The smooth muscle gamma-actin gene is androgen responsive in prostate epithelia.

Filmore R A; Dean D A; Zimmer W E

Department of Cell Biology and Neuroscience, University of South Alabama, Mobile, AL 36688, USA.

Gene expression (United States) 2002, 10 (5-6) p201-11, ISSN 1052-2166--Print Journal Code: 9200651

Contract/Grant No.: R01-H159956; PHS

Publishing Model Print

Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
Subfile: INDEX MEDICUS

Nkx 3.1 is an evolutionarily conserved vertebrate homolog of the Drosophila Nk-3 homeodomain gene bagpipe that is expressed by a variety of cells during early mammalian development and has been shown to be a critical factor for prostate development and function. Previous studies utilizing a heterologous cell transfection strategy from our laboratory identified the smooth muscle gamma-actin (SMGA) gene as a novel molecular target of Nkx 3.1 regulatory activity. In the studies presented here, SMGA gene activity and regulation were evaluated in normal and cancerous prostate epithelial cells. SMGA transcripts were demonstrated in prostate epithelia and SMGA mRNA levels were increased in androgen-responsive LNCaP cancer and normal prostate epithelial cells. SMGA gene transcriptional activity was androgen responsive in these cells and required a segment of the human SMGA promoter containing NKE and SRF (serum response factor) binding elements. This region of the human SMGA proximal promoter is well conserved across species and is synergistically activated by coexpression of Nkx 3.1 and SRF in heterologous CV-1 cells. SMGA transcription was not responsive to steroid in PC-3 prostate epithelial cancer cells, which do not express Nkx 3.1. However, SMGA transcription was influenced by expression of androgen receptor in these cells, a situation that allows the androgen-dependent expression of Nkx 3.1. Furthermore, SMGA gene activity was influenced by direct Nkx 3.1 expression in the PC-3 cells. Thus, SMGA gene activity in prostate epithelia is due, in part, to the androgen-dependent expression of Nkx 3.1. As such, our studies provide the initial description of Nkx 3.1 target gene regulatory activity in the prostate.

Tags: Male

Descriptors: *Actins--genetics--GE; *Actins--physiology--PH; *Androgens--metabolism--ME; *Epithelium--metabolism--ME; *Muscle, Smooth--metabolism--ME; *Prostate--metabolism--ME; Adolescent; Animals; Base Sequence; Blotting, Northern; Cell Line; Gene Expression Regulation; Homeodomain Proteins--metabolism--ME; Humans; Luciferases--metabolism--ME; Molecular Sequence Data; Promoter Regions (Genetics); Prostatic Neoplasms--metabolism--ME; Protein Binding; RNA, Messenger--metabolism--ME; Research Support, U.S. Gov't, P.H.S.; Sequence Homology, Nucleic Acid; Serum Response Factor--metabolism--ME; Transcription Factors--metabolism--ME; Transcription, Genetic; Transfection; Tumor Cells, Cultured

CAS Registry No.: 0 (Actins); 0 (Androgens); 0 (Homeodomain Proteins); 0 (NKX3-1 protein, human); 0 (RNA, Messenger); 0 (Serum Response Factor); 0 (Transcription Factors)

Enzyme No.: EC 1.13.12.- (Luciferases)

Record Date Created: 20021126

Record Date Completed: 20030513

3/9/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

12764111 PMID: 10871372

DNA-binding sequence of the human prostate-specific homeodomain protein NKX3.1.

Steadman D J; Giuffrida D; Gelmann E P

Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, 3800 Reservoir Road NW, Washington, DC 20007-2197, USA.

Nucleic acids research (ENGLAND) Jun 15 2000, 28 (12) p2389-95,

ISSN 1362-4962--Electronic Journal Code: 0411011

Contract/Grant No.: ES-09888; ES; NIEHS

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

NKX3.1 is a member of the NK class of homeodomain proteins and is most closely related to DROSOPHILA: NK-3. NKX3.1 has predominantly prostate-specific expression in the adult human. Previous studies suggested that NKX3.1 exerts a growth-suppressive effect on prostatic epithelial cells and controls differentiated glandular functions. Using a binding site selection assay with recombinant NKX3.1 protein we identified a TAAGTA consensus binding sequence that has not been reported for any other NK class homeoprotein. By electromobility shift assay we demonstrated that NKX3.1 preferentially binds the TAAGTA sequence rather than the binding site for Nkx2.1 (CAAGTG) or Msx1 (TAATTG). Using mutated binding sites in competitive gel shift assays, we analyzed the nucleotides in the TAAGTA consensus sequence that are important for NKX3.1 binding. The consensus binding site of a naturally occurring polymorphic NKX3.1 protein with arginine replaced by cysteine at position 52 was identical to the wild-type binding sequence. The binding affinities of wild-type and polymorphic NKX3.1 for the TAAGTA consensus site were very similar, with values of 20 and 22 nM, respectively. Wild-type and polymorphic NKX3.1 specifically repressed transcription of luciferase from a reporter vector with three copies of the NKX3.1-binding site upstream from a thymidine kinase promoter. The data show that among NK family proteins NKX3.1 binds a novel DNA sequence and can behave as an in vitro transcriptional repressor.

Tags: Male

Descriptors: *DNA--chemistry--CH; *DNA--metabolism--ME; *Homeodomain Proteins--metabolism--ME; *Oligodeoxyribonucleotides--chemistry--CH; *Spermatozoa--metabolism--ME; *Transcription Factors--metabolism--ME; Base Sequence; Binding Sites; Consensus Sequence; Genes, Tumor Suppressor; Humans; Kinetics; Oligodeoxyribonucleotides--metabolism--ME; Recombinant Proteins--metabolism--ME; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.

CAS Registry No.: 0 (Homeodomain Proteins); 0 (NKX3-1 protein, human); 0 (Oligodeoxyribonucleotides); 0 (Recombinant Proteins); 0 (Transcription Factors); 9007-49-2 (DNA)

Record Date Created: 20000727

Record Date Completed: 20000727

3/9/3 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

11130657 PMID: 8943214

Prostate-specific and androgen-dependent expression of a novel homeobox gene.

Bieberich C J; Fujita K; He W W; Jay G

Department of Virology, Jerome H. Holland Laboratory, Rockville, Maryland 20855, USA.

Journal of biological chemistry (UNITED STATES) Dec 13 1996, 271 (50) p31779-82, ISSN 0021-9258--Print Journal Code: 2985121R

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

A new member of the mouse NK family of homeobox genes that is related to Drosophila NK-3 has been identified. Expression of this gene, termed Nkx-3.1, is largely restricted to the prostate gland in adult animals. The level of Nkx-3.1 mRNA decreases markedly in response to castration, suggesting that its expression is androgen-dependent. In situ hybridization analyses demonstrated that expression of Nkx-3.1 in the prostate is confined to epithelial cells. In newborns, Nkx-3.1 mRNA is detected in the urethral epithelium that is being induced by the surrounding mesenchyme to invaginate to form prostatic buds. Together, these observations suggest that the Nkx-3.1 protein, which likely functions as a transcription factor, plays a prominent role both in the initiation of prostate development and in the maintenance of the differentiated state of prostatic epithelial cells.

Tags: Male

Descriptors: *Androgens--metabolism--ME; *Genes, Homeobox; *Homeodomain Proteins--genetics--GE; *Prostate--metabolism--ME; *Transcription Factors --genetics--GE; Amino Acid Sequence; Animals; Animals, Newborn; Blotting, Northern; Drosophila Proteins; Gene Expression Regulation, Developmental; In Situ Hybridization; Mice; Molecular Sequence Data; RNA, Messenger --metabolism--ME

Molecular Sequence Databank No.: GENBANK/U73460

CAS Registry No.: 0 (Androgens); 0 (Drosophila Proteins); 0 (Homeodomain Proteins); 0 (Nkx3-1 protein, mouse); 0 (RNA, Messenger); 0 (Transcription Factors); 0 (vnd protein, Drosophila)

Record Date Created: 19970117

Record Date Completed: 19970117

3/9/4 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0014501189 BIOSIS NO.: 200300469908

Human NK-3 related prostate specific gene-1

AUTHOR: He Wei-Wu (Reprint); Carter Kenneth C

JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents 1274 (2): Sep. 9, 2003 2003

MEDIUM: e-file

PATENT NUMBER: US 6617129 PATENT DATE GRANTED: September 09, 2003 20030909

PATENT CLASSIFICATION: 435-691 PATENT ASSIGNEE: Human Genome Sciences,

Inc. PATENT COUNTRY: USA

ISSN: 0098-1133 (ISSN print)

DOCUMENT TYPE: Patent

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The present invention relates to a novel member of the NK family of homeobox genes. In particular, isolated nucleic acid molecules are provided encoding the human NK-3 prostate specific gene 1 (NKX3.1) protein. NKX3.1 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of NKX3.1 activity. Also provided are diagnostic methods for detecting prostate cancer and other cancers and therapeutic methods for prostate cancer and other cancers.

DESCRIPTORS:

MAJOR CONCEPTS: Medical Genetics--Allied Medical Sciences; Methods and

Techniques; Oncology--Human Medicine, Medical Sciences
BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGANISMS: human (Hominidae)
COMMON TAXONOMIC TERMS: Animals; Chordates; Humans; Mammals; Primates; Vertebrates
DISEASES: prostate cancer--neoplastic disease, reproductive system disease/male, urologic disease, diagnosis, therapy
MESH TERMS: Prostatic Neoplasms (MeSH)
CHEMICALS & BIOCHEMICALS: human NK-3 prostate specific gene 1 protein--activity
GENE NAME: human NK-3 prostate specific gene 1 (Hominidae) {human NKX3.1}
CONCEPT CODES:
03508 Genetics - Human
12504 Pathology - Diagnostic
12512 Pathology - Therapy
15506 Urinary system - Pathology
16506 Reproductive system - Pathology
24001 Neoplasms - Diagnostic methods
24004 Neoplasms - Pathology, clinical aspects and systemic effects
24008 Neoplasms - Therapeutic agents and therapy
BIOSYSTEMATIC CODES:
86215 Hominidae

3/9/5 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0010377488 BIOSIS NO.: 199699011548
Pharmacological characterization of tachykinin NK-2 receptors on isolated human urinary bladder, prostatic urethra and prostate
AUTHOR: Palea Stefano (Reprint); Corsi Mauro; Artibani Walter; Ostardo Edoardo; Pietra Claudio
AUTHOR ADDRESS: Glaxo Res. Lab., Via Fleming 4, 37135 Verona, Italy**Italy
JOURNAL: Journal of Pharmacology and Experimental Therapeutics 277 (2): p 700-705 1996 1996
ISSN: 0022-3565
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The contractile effect of two highly potent, selective and peptidase-resistant neurokinin (NK) 1 and NK-2 receptor agonists, namely delta-Aminovaleryl-(L-Pro-9, N-MeLeu-10)substance P-(7-11) (GR 73632) and Lys-3, Gly-8-R-gamma-lactam-Leu-9)NKA-(3-10) GR 64349), respectively, was investigated on smooth muscle strips dissected from specimens of human detrusor, prostatic urethra and prostate. Furthermore, the potencies of two peptidic NK-2 receptor agonists, GR 87389 and L 659,837, in antagonizing GR 64349-induced contractions were compared in these three tissues. In human detrusor muscle the rank order of agonist potency was: (beta Ala-8 (NKA-(4-10)) gt GR 64349 mchgt NKA-(4-10) mchgt SP = GR 73632 mchgt SP-methylester. The NK-2 receptor antagonist, GR 87389, antagonized GR 64349-induced contractions in a competitive manner, whereas L 659,837 was a noncompetitive antagonist. In the prostatic urethra the rank order of agonist potency was GR 64349.gt NKA-(4-10) gt SP gt GR 73632, whereas in the prostate it was: GR 64349 mchgt (beta Ala-8 (NKA-(4-10)) gt NKA-(4-10) gt SP; GR 73632 was ineffective up to 30 mu-M. In the prostatic urethra and in the prostate GR 87389 was a noncompetitive antagonist with a potency similar to that exhibited in the detrusor. On

the contrary, L 659,837 appeared to be a competitive antagonist in the prostate and in the prostatic urethra, having approximately the similar potency in these two tissues. The selective NK-3 agonist senktide was ineffective up to 30 μ M in all three tissues. These results are discussed in the view of the proposed NK-2 receptor subtypes and considering possible therapeutic implications in the treatment of urinary bladder disorders.

REGISTRY NUMBERS: 133156-06-6: GR 73632; 137593-52-3: GR 64349; 153569-98-3
: GR 87389; 125989-10-8: L 659,837

DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Cell Biology;
Endocrine System--Chemical Coordination and Homeostasis; Membranes--
Cell Biology; Muscular System--Movement and Support; Nervous System--
Neural Coordination; Pharmacology; Reproductive System--Reproduction;
Urinary System--Chemical Coordination and Homeostasis

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata,
Animalia

ORGANISMS: Hominidae (Hominidae)

COMMON TAXONOMIC TERMS: Animals; Chordates; Humans; Mammals; Primates;
Vertebrates

CHEMICALS & BIOCHEMICALS: GR 73632; GR 64349; GR 87389; L 659,837

MISCELLANEOUS TERMS: DETRUSOR MUSCLE; GR 64349; GR 73632; GR 87389; L
659,837; SMOOTH MUSCLE; THERAPEUTIC POTENTIAL

CONCEPT CODES:

02506 Cytology - Animal
10060 Biochemistry studies - General
10064 Biochemistry studies - Proteins, peptides and amino acids
10506 Biophysics - Molecular properties and macromolecules
10508 Biophysics - Membrane phenomena
12512 Pathology - Therapy
15504 Urinary system - Physiology and biochemistry
16504 Reproductive system - Physiology and biochemistry
17020 Endocrine - Neuroendocrinology
17504 Muscle - Physiology and biochemistry
20504 Nervous system - Physiology and biochemistry
22005 Pharmacology - Clinical pharmacology
22028 Pharmacology - Reproductive system
22032 Pharmacology - Urinary system

BIOSYSTEMATIC CODES:

86215 Hominidae

?